ANAVEX®2-73 (Blarcamesine), which targets sigma-1 and M1 muscarinic receptors, has also demonstrated its disease-modifying activity in AD transgenic mice (3xTg-AD), including reducing amyloid and tau pathologies as well as improving cognitive deficits.51,52 The results of its Phase 2B/3 study, presented at the Clinical Trials on Alzheimer’s Disease (CTAD) Congress 2022, showed that 48 weeks of blarcamesine treatment significantly reduced cognitive decline in patients with early AD. Here, MAPT is linked to Mental deterioration.